Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JKN2501
- Development stage
- Phase 1
- Lead developer
- Joincare Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
JKN2501 is an investigational intravenous small-molecule, broad-spectrum **beta-lactamase inhibitor** being developed in China for use with meropenem against serious resistant bacterial infections. It does not directly kill bacteria; instead, it inhibits bacterial beta-lactamases across Ambler classes A, B, C, and D, including KPC, NDM metallo-beta-lactamases, and OXA enzymes, thereby protecting meropenem from enzymatic hydrolysis and restoring its antibacterial activity. JKN2501 has completed a Phase 1 healthy-volunteer study for complicated urinary tract infection development and is in a randomized Phase 2a study with meropenem for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. ([static.cninfo.com.cn](https://static.cninfo.com.cn/finalpage/2026-05-07/1225279757.PDF))
- Other names
- JKN-2501JKN2501JKN 2501
02
Targets
KPC (Klebsiella pneumoniae carbapenemase)NDM-1 (NDM-1 beta-lactamase)OXA (Oxacillin-hydrolyzing beta-lactamase)
Beyond the preview
Go deeper on JKN2501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JKN2501.